ALPHARETTA, Ga. - Avanos Medical, Inc. (NYSE: NYSE:AVNS), a medical technology company, announced its third-quarter financial results for 2024, and the retirement of CEO Joe Woody. Michael Greiner, the company's CFO and Chief Transformation Officer, will serve as interim CEO.
The company reported a slight decrease in total net sales from continuing operations at $170.4 million, a 0.5% drop from the previous year. However, net income from continuing operations showed improvement, recording $5.9 million compared to a net loss of $8.8 million in the same period last year.
Adjusted net income from continuing operations was $16.7 million, up from $14.0 million a year ago, and adjusted EBITDA increased to $30.6 million from $27.8 million. The diluted earnings per share from continuing operations were $0.12, a positive shift from a loss per share of $0.19 in the prior year.
Despite some areas of strong sales performance, particularly in the digestive health business, underperformance in the surgical pain category affected overall sales. The company's gross profit margin decreased primarily due to costs related to restructuring initiatives and lower pricing for its hyaluronic acid products.
For the nine months ended September 30, 2024, Avanos reported net sales of $508.2 million, a 1.6% increase from the prior year period. The company also saw a significant turnaround in net income from continuing operations, reporting $10.7 million compared to a net loss of $20.9 million in the previous year.
Looking ahead, Avanos anticipates revenue from continuing operations for the year to be between $683 million and $688 million, with adjusted diluted earnings per share from continuing operations expected to be between $1.30 and $1.35.
The company's balance sheet showed a cash balance of $89.0 million and a total debt of $162.0 million, net of unamortized discounts.
The financial results and CEO retirement announcement are based on a press release statement from Avanos Medical, Inc. The company will host a conference call to discuss the quarterly results further.
In other recent news, Avanos Medical has reported a 2.6% increase in sales from continuing operations, totaling $172 million in the second quarter of 2024. The company's Digestive Health portfolio displayed robust performance with nearly 9% organic growth, while the Pain Management and Recovery portfolio registered a 2% normalized organic sales growth. Avanos Medical has also reaffirmed its full-year guidance for 2024, keeping in line with expectations for mid single-digit organic growth and adjusted gross margins between 59.5% and 60.5%.
In the financial domain, the company reported a positive free cash flow of $22 million for the quarter. In terms of future expectations, Avanos Medical has adjusted its 2024 free cash flow projection to approximately $70 million due to higher charges and inventory, with financial objectives for 2025 including mid single-digit growth, gross margins over 60%, and free cash flow of around $100 million.
A noteworthy development is Avanos Medical's active pursuit of strategic M&A opportunities, particularly in Digestive Health, and openness to share repurchases. Despite discontinuing some products, these recent developments show Avanos Medical's commitment to a proactive approach to growth and shareholder value.
InvestingPro Insights
To complement Avanos Medical's third-quarter financial results, InvestingPro data provides additional context for investors. Despite the slight decrease in total net sales, InvestingPro Tips highlight that Avanos Medical's net income is expected to grow this year, aligning with the company's improved net income from continuing operations reported in the third quarter.
The company's balance sheet strength is underscored by an InvestingPro Tip indicating that liquid assets exceed short-term obligations, which is consistent with the reported cash balance of $89.0 million against a total debt of $162.0 million. Additionally, InvestingPro notes that Avanos operates with a moderate level of debt, providing further insight into the company's financial position.
Interestingly, while the article doesn't mention share buybacks, an InvestingPro Tip reveals that management has been aggressively buying back shares, suggesting confidence in the company's future prospects. This information, combined with the high shareholder yield noted by InvestingPro, may be of particular interest to investors considering the company's value proposition.
For those seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for Avanos Medical, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.